Lastly, when only considering variants with known or likely tumorigenic potential, we found a significant enrichment of KRAS and NF1 mutations in metastatic tumors (KRAS—1.9% in metastases vs. 1.1% in local disease, p = 0.0045; NF1–4.7% vs. 3.3%, p = 0.013, S5 Table), which suggests a potential role for the ras/MAPK pathway in metastasis [30]. The gene discussed is KRAS; the disease is metastatic neoplasm.